Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Earnings Data
Report Date
Mar 03, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
6.36Last Year’s EPS
6.6Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Jazz Pharmaceuticals had a strong third quarter with record revenue, multiple FDA approvals, and robust growth in key products. The company also addressed legal challenges with settlements and continued to advance its pipeline. However, concerns about future competition from generics and a decline in Zepzelca sales present challenges.Company Guidance
Record Revenue Achievement
Achieved highest ever revenue for the quarter at over $1.1 billion, driven by robust growth from Xywav, Epidiolex, and the launch of Modeyso.
FDA Approvals and Product Launches
Received FDA approvals for Modeyso and Zepzelca; Modeyso generated $11 million in net product sales shortly after approval.
Strong Performance of Key Products
Xywav net product sales grew 11% year-over-year to $431 million. Epidiolex net product sales were $303 million, a 20% increase compared to the third quarter of 2024.
Pipeline and Strategic Developments
Strengthened epilepsy pipeline through a licensing agreement with Saniona. Upcoming top line results from the Phase III zanidatamab HERIZON trial in GEA expected later this quarter.
Litigation Settlements
Reached settlement agreements across Xyrem antitrust litigation and litigation with Avadel, allowing focus on strategic execution.
JAZZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JAZZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $137.22 | $134.05 | -2.31% |
Aug 05, 2025 | $113.20 | $105.93 | -6.42% |
May 06, 2025 | $111.17 | $101.44 | -8.75% |
Feb 25, 2025 | $139.67 | $144.17 | +3.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Jazz Pharmaceuticals (JAZZ) report earnings?
Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).
What is Jazz Pharmaceuticals (JAZZ) earnings time?
Jazz Pharmaceuticals (JAZZ) earnings time is at Mar 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAZZ EPS forecast?
JAZZ EPS forecast for the fiscal quarter 2025 (Q4) is 6.36.